Article

TKI-Tolerant Persisters Emerge from a PKCα-Dependent and Highly Plastic Subpopulation of Stem-Like Cells in NSCLC

2026-05-21

Abstract excerpt

Reversible drug-tolerant persister states are emerging as key drivers of limited therapeutic durability, offering a complementary non-genetic perspective distinct from traditional models of acquired resistance. This is of particular interest in lung adenocarcinoma where EGFR tyrosine kinase inhibitors (TKIs) elicit dramatic responses, yet residual surviving cells persist and ultimately seed relapse. To define mech...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bae98b7c-cd9f-583e-bb63-f37cb6e1f62b
DOI: 10.64898/2026.05.20.726497

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

TKI-Tolerant Persisters Emerge from a PKCα-Dependent and Highly Plastic Subpopulation of Stem-Like Cells in NSCLCDOI 10.64898/2026.05.20.726497Read

Drug-Tolerant Persister Cells in Cancer Therapy ResistanceSemantic proximity Read

Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.Semantic proximity Read

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read

Gene Panel of Persister Cells as a Prognostic Indicator for Tumor Repopulation After RadiationSemantic proximity Read

Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.Semantic proximity Read

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read

ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.Semantic proximity Read

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read

Pharmacological agents targeting drug-tolerant persister cells in cancerSemantic proximity Read

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in <i>EGFR</i> -mutant NSCLCSemantic proximity Read

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programsSemantic proximity Read